Blog
Read our latest blog posts on biotech, AI, and funding rare disease research.
The science of drug development: Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared some lessons learned from developing portfolio management and probability assessment approaches.
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future.
How to improve biopharma business development with AI-powered due diligence
Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their
Pharma portfolio analytics in a gen AI world
I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges,
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapidly advancing in science, know-how, + talent. Chinese assets are poised
